Patents Assigned to PROLYNX LLC
  • HIGH-THROUGHPUT MICROEMULSIFICATION MEMBRANE
    Publication number: 20240181397
    Abstract: The present disclosure is related to high-throughput membranes for preparation of microdroplet emulsions and microparticle suspensions and apparatus and systems comprising the same. Also provided are methods of preparing microdroplet emulsions and microparticle suspensions.
    Type: Application
    Filed: March 18, 2022
    Publication date: June 6, 2024
    Applicant: ProLynx LLC
    Inventors: Jeffrey C. HENISE, Brian YAO
  • SYNERGISTIC CANCER TREATMENT
    Publication number: 20240082436
    Abstract: Conjugates of topoisomerase I inhibitors linked to a macromolecule through a linkage that undergo beta elimination in situ in combination with one or more of an assessed defect in DNA damage response (DDR) in a subject bearing cancer, a cell cycle checkpoint inhibitor and/or a DDR inhibitor provides improved outcomes for cancer-bearing subjects.
    Type: Application
    Filed: July 11, 2023
    Publication date: March 14, 2024
    Applicant: ProLynx LLC
    Inventors: Daniel V. SANTI, Shaun FONTAINE
  • EXTENDED RELEASE HYDROGEL CONJUGATES OF C-NATRIURETIC PEPTIDES
    Publication number: 20240041982
    Abstract: Provided herein are extended release hydrogel conjugates of c-natriuretic peptides, methods of preparation thereof, and methods of use thereof.
    Type: Application
    Filed: November 24, 2021
    Publication date: February 8, 2024
    Applicant: ProLynx LLC
    Inventors: Eric L. SCHNEIDER, Brian R. HEARN, Daniel V. SANTI
  • PROTOCOL FOR MINIMIZING TOXICITY OF COMBINATION DOSAGES AND IMAGING AGENT FOR VERIFICATION
    Publication number: 20230321286
    Abstract: Advantage is taken of the enhanced permeability and retention effect (EPR effect) to shield normal tissue from exposure to combinations of chemotherapeutic agents. Imaging agents that exhibit the enhanced permeability and retention (EPR) effect in solid tumors are useful in mimicking the behavior of chemotherapeutic or other drugs for treatment of said tumor conjugated to carriers of similar size and shape to the carriers of said imaging agents.
    Type: Application
    Filed: March 7, 2023
    Publication date: October 12, 2023
    Applicant: ProLynx LLC
    Inventors: Brian HEARN, Daniel V. SANTI, Shaun FONTAINE, Gary W. ASHLEY
  • Synergistic cancer treatment
    Patent number: 11730836
    Abstract: Conjugates of topoisomerase I inhibitors linked to a macromolecule through a linkage that undergo beta elimination in situ in combination with one or more of an assessed defect in DNA damage response (DDR) in a subject bearing cancer, a cell cycle checkpoint inhibitor and/or a DDR inhibitor provides improved outcomes for cancer-bearing subjects.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: August 22, 2023
    Assignee: ProLynx LLC
    Inventors: Daniel V. Santi, Shaun Fontaine
  • HYDROGELS WITH BIODEGRADABLE CROSSLINKING
    Publication number: 20230135347
    Abstract: Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.
    Type: Application
    Filed: September 7, 2022
    Publication date: May 4, 2023
    Applicant: ProLynx LLC
    Inventors: Gary W. ASHLEY, Daniel V. SANTI, Jeffrey C. HENISE
  • CONJUGATED INHIBITORS OF DNA DAMAGE RESPONSE
    Publication number: 20220331437
    Abstract: Provided herein are releasable conjugates of inhibitors of DNA damage response suitable for use as therapeutic agents in the treatment of disease.
    Type: Application
    Filed: August 28, 2020
    Publication date: October 20, 2022
    Applicant: ProLynx LLC
    Inventors: Shaun D. FONTAINE, Brian R. HEARN, Daniel V. SANTI
  • Hydrogels with biodegradable crosslinking
    Patent number: 11454861
    Abstract: Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: September 27, 2022
    Assignee: ProLynx LLC
    Inventors: Gary W. Ashley, Daniel V. Santi, Jeffrey C. Henise
  • IMPROVED CONJUGATION LINKERS
    Publication number: 20220280654
    Abstract: Provided are ?-eliminative linkers suitable for the conjugation of small molecule, peptide, and protein and compounds comprising the linkers.
    Type: Application
    Filed: April 3, 2020
    Publication date: September 8, 2022
    Applicant: ProLynx LLC
    Inventors: Gary W. ASHLEY, Brian HEARN, Shaun FONTAINE, Eric L. SCHNEIDER
  • STEAM STERILIZATION OF HYDROGELS CROSSLINKED BY BETA-ELIMINATIVE LINKERS
    Publication number: 20220265873
    Abstract: Methods for the steam sterilization of hydrogels crosslinked with a beta-eliminative linker without the drawback of significant degradation are provided.
    Type: Application
    Filed: August 7, 2020
    Publication date: August 25, 2022
    Applicant: ProLynx LLC
    Inventors: Jeffrey C. HENISE, Gary W. ASHLEY, Brian YAO
  • SLOW-RELEASE CYTOKINE CONJUGATES
    Publication number: 20220193253
    Abstract: This disclosure generally relates to releasable cytokine conjugates and methods of using the same.
    Type: Application
    Filed: April 24, 2020
    Publication date: June 23, 2022
    Applicant: ProLynx LLC
    Inventors: John A. HANGASKY, III, Samuel J. PFAFF, Daniel V. SANTI
  • Hydrogels with biodegradable crosslinking
    Patent number: 11181803
    Abstract: Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: November 23, 2021
    Assignee: ProLynx LLC
    Inventors: Gary W. Ashley, Daniel V. Santi, Jeffrey C. Henise
  • Hydrogels with biodegradable crosslinking
    Patent number: 11179470
    Abstract: Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: November 23, 2021
    Assignee: ProLynx LLC
    Inventors: Gary W. Ashley, Daniel V. Santi, Jeffrey C. Henise
  • SYNERGISTIC CANCER TREATMENT
    Publication number: 20200397778
    Abstract: Conjugates of topoisomerase I inhibitors linked to a macromolecule through a linkage that undergo beta elimination in situ in combination with one or more of an assessed defect in DNA damage response (DDR) in a subject bearing cancer, a cell cycle checkpoint inhibitor and/or a DDR inhibitor provides improved outcomes for cancer-bearing subjects.
    Type: Application
    Filed: January 11, 2019
    Publication date: December 24, 2020
    Applicant: ProLynx LLC
    Inventors: Daniel V. SANTI, Shaun FONTAINE
  • PROTOCOL FOR MINIMIZING TOXICITY OF COMBINATION DOSAGES AND IMAGING AGENT FOR VERIFICATION
    Publication number: 20200360545
    Abstract: Advantage is taken of the enhanced permeability and retention effect (EPR effect) to shield normal tissue from exposure to combinations of chemotherapeutic agents. Imaging agents that exhibit the enhanced permeability and retention (EPR) effect in solid tumors are useful in mimicking the behavior of chemotherapeutic or other drugs for treatment of said tumor conjugated to carriers of similar size and shape to the carriers of said imaging agents.
    Type: Application
    Filed: January 11, 2019
    Publication date: November 19, 2020
    Applicant: ProLynx LLC
    Inventors: Brian HEARN, Daniel V. SANTI, Shaun FONTAINE, Gary W. ASHLEY
  • EXTENDED RELEASE CONJUGATES OF EXENATIDE ANALOGS
    Publication number: 20200164083
    Abstract: Extended-release conjugates of stabilized GLP-1 agonists balance agonist stability with release rates to provide long lasting administration to treat diabetes and related conditions on once-a-month or less frequent dosing schedules.
    Type: Application
    Filed: March 16, 2017
    Publication date: May 28, 2020
    Applicant: ProLynx LLC
    Inventors: Eric L. SCHNEIDER, Brian HEARN, Jeffrey C. HENISE, Gary W. ASHLEY, Daniel V. SANTI
  • HYDROGELS WITH BIODEGRADABLE CROSSLINKING
    Publication number: 20200054756
    Abstract: Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.
    Type: Application
    Filed: August 30, 2019
    Publication date: February 20, 2020
    Applicant: ProLynx LLC
    Inventors: Gary W. ASHLEY, Daniel V. SANTI, Jeffrey C. HENISE
  • Conjugates of somatostatin analogues
    Patent number: 10413594
    Abstract: Conjugates of carriers and hydrogels for controlling the biological half-life of somatostatin and its analogs are disclosed.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: September 17, 2019
    Assignee: ProLynx LLC
    Inventors: Eric L. Schneider, Brian Hearn, Gary W. Ashley, Daniel V. Santi
  • Hydrogels with biodegradable crosslinking
    Patent number: 10398779
    Abstract: Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: September 3, 2019
    Assignee: ProLynx LLC
    Inventors: Gary W. Ashley, Daniel V. Santi, Jeffrey C. Henise
  • HYDROGELS WITH BIODEGRADABLE CROSSLINKING
    Publication number: 20190209691
    Abstract: Hydrogels that degrade under appropriate conditions of pH and temperature by virtue of crosslinking compounds that cleave through an elimination reaction are described. The hydrogels may be used for delivery of various agents, such as pharmaceuticals.
    Type: Application
    Filed: January 15, 2019
    Publication date: July 11, 2019
    Applicant: ProLynx LLC
    Inventors: Gary W. ASHLEY, Daniel V. SANTI, Jeffrey C. HENISE